| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11908-012-0276-2 |
| P698 | PubMed publication ID | 22851006 |
| P2093 | author name string | Steven M Opal | |
| Steven P Larosa | |||
| P2860 | cites work | Activation of endothelial cell protease activated receptor 1 by the protein C pathway | Q24299215 |
| Toll-like receptor signalling | Q24570126 | ||
| Pathophysiology, staging and therapy of severe sepsis in baboon models | Q27024559 | ||
| Binding of superantigen toxins into the CD28 homodimer interface is essential for induction of cytokine genes that mediate lethal shock | Q27321007 | ||
| Th17 and regulatory T cells in mediating and restraining inflammation | Q27687428 | ||
| Coagulation abnormalities in critically ill patients | Q28199912 | ||
| The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses | Q29614469 | ||
| Resolution of inflammation: the beginning programs the end | Q29615695 | ||
| Nonresolving inflammation | Q29616352 | ||
| The inflammasomes: guardians of the body | Q29618003 | ||
| Resolvin E1 and protectin D1 activate inflammation-resolution programmes | Q29618679 | ||
| The pathophysiology and treatment of sepsis | Q29619103 | ||
| Thrombin signalling and protease-activated receptors | Q29619601 | ||
| Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis | Q33389544 | ||
| Changes in peroxisome proliferator-activated receptor-gamma activity in children with septic shock | Q33604169 | ||
| Inhibition of bacterial superantigens by peptides and antibodies | Q34005961 | ||
| IL-7 promotes T cell viability, trafficking, and functionality and improves survival in sepsis. | Q34039180 | ||
| IL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis. | Q34120958 | ||
| Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension | Q34171148 | ||
| Acetylcholine-synthesizing T cells relay neural signals in a vagus nerve circuit | Q34216728 | ||
| Targeting of B and T lymphocyte associated (BTLA) prevents graft-versus-host disease without global immunosuppression | Q34340643 | ||
| Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins | Q34522097 | ||
| Therapeutic potential of targeting the complement cascade in critical care medicine | Q35052438 | ||
| Role of C5a-C5aR interaction in sepsis | Q35608139 | ||
| Innate response activator B cells protect against microbial sepsis. | Q35757819 | ||
| Inferences, questions and possibilities in Toll-like receptor signalling | Q35829752 | ||
| Immunosuppression in patients who die of sepsis and multiple organ failure | Q35991015 | ||
| Human mesenchymal stem cells reduce mortality and bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes | Q35994803 | ||
| A matrix metalloprotease-PAR1 system regulates vascular integrity, systemic inflammation and death in sepsis. | Q36088900 | ||
| Alkaline phosphatase for treatment of sepsis-induced acute kidney injury: a prospective randomized double-blind placebo-controlled trial | Q36093514 | ||
| Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation | Q36100021 | ||
| Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review | Q36392609 | ||
| Apoptosis and caspases regulate death and inflammation in sepsis | Q36622618 | ||
| Stem cells in sepsis and acute lung injury. | Q36916458 | ||
| Host-pathogen interactions in sepsis | Q37026360 | ||
| Molecular biology of inflammation and sepsis: a primer | Q37339671 | ||
| T cells are potent early mediators of the host response to sepsis. | Q37729791 | ||
| Immunodeficiency and genetic defects of pattern-recognition receptors | Q37826190 | ||
| Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial | Q38380791 | ||
| TLR-mediated B cell activation results in ectopic CLIP expression that promotes B cell-dependent inflammation | Q39179342 | ||
| The sepsis seesaw: tilting toward immunosuppression | Q42035078 | ||
| Copy number variation and susceptibility to complex traits | Q42245090 | ||
| Bovine intestinal alkaline phosphatase attenuates the inflammatory response in secondary peritonitis in mice | Q42586828 | ||
| Immunotherapy for sepsis--a new approach against an ancient foe. | Q42802907 | ||
| Dephosphorylation of endotoxin by alkaline phosphatase in vivo. | Q42839781 | ||
| Improved survival in experimental sepsis with an orally administered inhibitor of apoptosis | Q43684928 | ||
| Protective effects of C5a blockade in sepsis | Q44260666 | ||
| Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. | Q44486370 | ||
| AB103, a CD28 antagonist peptide: a new therapeutic agent in a model of severe sepsis | Q46059986 | ||
| Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. | Q46180032 | ||
| Peroxisome proliferator-activated receptor-gamma antagonists GW9662 and T0070907 reduce the protective effects of lipopolysaccharide preconditioning against organ failure caused by endotoxemia | Q46950036 | ||
| Functional innervation of hepatic iNKT cells is immunosuppressive following stroke. | Q48896296 | ||
| C1-esterase inhibitor infusion increases survival rates for patients with sepsis*. | Q50993962 | ||
| PyNTTTTGT prototype oligonucleotide IMT504, a novel effective adjuvant of the FMDV DNA vaccine. | Q51748149 | ||
| Affinity apheresis for treatment of bacteremia caused by Staphylococcus aureus and/or methicillin-resistant S. aureus (MRSA). | Q54362077 | ||
| Protection against an Escherichia coli-induced sepsis by alkaline phosphatase in mice. | Q54502904 | ||
| Protective role of peroxisome proliferator-activated receptor-β/δ in septic shock. | Q54657506 | ||
| Drotrecogin alfa (activated) in adults with septic shock. | Q55056165 | ||
| Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation | Q63859520 | ||
| Safety and efficacy of affinity-purified, anti–tumor necrosis factor-α, ovine fab for injection (CytoFab) in severe sepsis* | Q64132590 | ||
| The inhibitory effect of recombinant human soluble thrombomodulin on initiation and extension of coagulation--a comparison with other anticoagulants | Q73307869 | ||
| Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial | Q79292898 | ||
| Regulation of immune responses by T cells | Q82843548 | ||
| Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis | Q84255932 | ||
| P433 | issue | 5 | |
| P921 | main subject | sepsis | Q183134 |
| P304 | page(s) | 474-483 | |
| P577 | publication date | 2012-10-01 | |
| P1433 | published in | Current infectious disease reports | Q26842136 |
| P1476 | title | Immune aspects of sepsis and hope for new therapeutics | |
| P478 | volume | 14 |
| Q41564904 | Ginsenoside Rg3 attenuates sepsis-induced injury and mitochondrial dysfunction in liver via AMPK-mediated autophagy flux |
| Q38165517 | Lipid mediators in immune dysfunction after severe inflammation |
| Q38131458 | Noncanonical Nuclear Factor Kappa B (NF-κB) Signaling and Potential for Therapeutics in Sepsis |
| Q33703008 | Pleural innate response activator B cells protect against pneumonia via a GM-CSF-IgM axis |
| Q40510040 | Prostaglandin E₂ constrains systemic inflammation through an innate lymphoid cell-IL-22 axis |
Search more.